Research Analysts Issue Forecasts for ContraFect Co.’s Q2 2022 Earnings (NASDAQ:CFRX)

ContraFect Co. (NASDAQ:CFRX – Get Rating) – Equities research analysts at SVB Leerink lowered their Q2 2022 earnings per share (EPS) estimates for shares of ContraFect in a research note issued to investors on Monday, May 16th. SVB Leerink analyst R. Ruiz now anticipates that the biotechnology company will post earnings of ($0.27) per share for the quarter, down from their prior estimate of ($0.23). SVB Leerink has a “Outperform” rating and a $9.00 price objective on the stock. SVB Leerink also issued estimates for ContraFect’s Q4 2022 earnings at ($0.12) EPS, FY2022 earnings at ($1.09) EPS, FY2023 earnings at ($1.05) EPS and FY2025 earnings at $2.00 EPS.

Separately, StockNews.com started coverage on shares of ContraFect in a research note on Friday, May 13th. They issued a “sell” rating for the company.

CFRX stock opened at $3.16 on Thursday. ContraFect has a one year low of $2.11 and a one year high of $4.76. The firm has a 50-day simple moving average of $3.67 and a two-hundred day simple moving average of $3.25.

ContraFect (NASDAQ:CFRX – Get Rating) last issued its earnings results on Monday, May 16th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.20).

Hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of ContraFect by 1.2% during the first quarter. Goldman Sachs Group Inc. now owns 407,031 shares of the biotechnology company’s stock worth $1,486,000 after purchasing an additional 4,948 shares in the last quarter. State Street Corp grew its holdings in shares of ContraFect by 33.5% during the first quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock worth $474,000 after buying an additional 32,563 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of ContraFect by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,551,898 shares of the biotechnology company’s stock worth $5,664,000 after purchasing an additional 11,064 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in ContraFect by 62.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 112,782 shares of the biotechnology company’s stock valued at $412,000 after buying an additional 43,564 shares in the last quarter. Finally, White Pine Capital LLC grew its holdings in shares of ContraFect by 15.3% in the first quarter. White Pine Capital LLC now owns 356,217 shares of the biotechnology company’s stock valued at $1,300,000 after purchasing an additional 47,354 shares during the period. Institutional investors and hedge funds own 59.39% of the company’s stock.

ContraFect Company Profile (Get Rating)

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia.

Recommended Stories